Background: Neonatal diabetes mellitus (NDM) is a monogenic form of diabetes mellitus. Until now, patients in developing countries who had this condition had been misdiagnosed as having type 1 diabetes mellitus and accordingly directed to erroneous, ineffective, and costly therapeutic regimens.
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Neonatal DM (NDM) is an entity of monogenic diabetes mellitus caused by insufficient insulin production that occurs in the first 6 months after birth. It is a rare disease with an estimated incidence of 1 in 400,000 in neonates. 2 It can be classified into 2 distinct clinical groups, namely, transient neonatal diabetes mellitus (TNDM) and permanent neonatal diabetes mellitus (PNDM). 3, 4 Considerable overlap occurs between the 2 groups, such that the transient group cannot be differentiated from the permanent group based on clinical features.
PND has been elucidated by variations that occur at the molecular level. More than 20 pathogenic genes have been identified in PND, the most common of which are KCNJ11 (OMIM: 600937) and ABCC8 (OMIM: 600509), accounting for 40% to 60% of all genes involved in PNDM. These genes encode the Kir6.2 and SUR1 subunits of the pancreatic b-cell KATP channel, respectively. The pancreatic b-cell KATP channel is involved in regulating insulin secretion in response to variations in plasma glucose levels, and thus is an important controller of glucose homeostasis. 7 As previously mentioned, it consists of 2 vital subunits, namely, Kir6.2, and SUR1. In case of increased metabolism, the binding of ATP to Kir6.2 results in KATP channel closure, lack of K þ efflux, and membrane depolarization that stimulates electrical activity with subsequent insulin secretion. By contrast, sulfonylureas, potassium channel openers, and magnesium nucleotides bind to SUR1 via its 2 cytosolic nucleotide-binding domains (NBDs). 8 After the detection of the mutations of b-cell KATP channel subunits, more than 90% of patients were shifted to treatment with sulfonylurea. Most patients showed remarkable improvement in their clinical state and bloodglucose-level control. Minimal adverse effects (eg, tooth discoloration and transient diarrhea) have been reported. 9 Hence, a strong tool to identify PNDM is molecular analysis of KCNJ11 and ABCC8 gene pathological variant. 10 So far, the activating mutation of KCNJ11 has been delineated as the most common pathological variant.
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Our country, Egypt, carries the tremendous responsibility of a national healthcare system run by the government. This burden is particularly heavy given the number of individuals with chronic diseases, such as diabetes mellitus, that require lifelong treatment. Until recently, patients in Egypt who have PNDM were misdiagnosed as having type 1 diabetes mellitus and accordingly were prescribed erroneous therapeutic regimens that are tedious, expensive, and often yield unsatisfactory results.
Within this context, this study aims to identify Egyptian patients with PNDM by detection of pathological variant in the KCNJ11 gene, as a means of determining which individuals could be targeted for modification of their treatment regimen.
Materials and Methods

Study Population
We performed a prospective cross-sectional observational study that included 17 ethnic Egyptian patients (ages 1 year to 16 years), recruited from the Diabetes Pediatric clinic of The National Research Centre, Cairo, Egypt. These patients previously had been diagnosed with DM before age 2 years.
The study was approved by the local ethics committee (according to the tenets of the World Medical Association Declaration of Helsinki). The concept of the study was fully explained to all parents and appropriate children, who then provided informed consent for peripheral blood withdrawal.
Patients with TNDM and patients with syndromic diabetes mellitus were excluded from the study. All patients were subjected to full history taking, as well as general and neurological examination.
Methodology
We collected 3 mL of blood from each subject individual in a sterile ethylenediaminetetraacetic acid (EDTA) vacutainer for the genotyping procedure. Specimens were stored at -80 � C until DNA extraction using a QIAamp DNA extraction kit (DNA Blood Mini Kits; QIAGEN n.v.). We measured DNA concentration using a spectrophotometer (Nanodropper 2000, Thermo Fisher Scientific Inc) at absorbance A260/ A280 ratio 1.3 to 1.7.
The intronless gene (1173 base pair [bp]) was amplified in 3 overlapping fragments using primers (forward and reverse primers supplied by QIAGEN n.v.). The sequences for fragments 1 through 3 were 1F 5 0 -CCG AGA GGA CTC TGC 
Results
Characteristics of the study subjects are shown in Table 1 . All case individuals had been born at full term and had an appropriate birth weight.
The present study identified 1 case individual with a pathological variant in the KCNJ11 gene (p.R201H). This patient had a G > A nucleotide substitution at position 602 (c.602G > A) of KCNJ11. This heterozygous missense pathological variant results in the substitution of arginine for histidine at codon 201 (p.R201H) and confirms a diagnosis of neonatal diabetes mellitus (NDM) due to a pathological variant in the Kir 6.2 subunit of the K ATP channel. The patient was a 10-year-old boy who had experienced vomiting, diarrhea, and polyuria at the age of 45 days. No family history of DM in his first-degree relatives was reported. He had no developmental delay or neurological manifestations. Insulin autoantibodies (IAA) and glutamic acid decarboxylase (GAD) antibody results were negative. The body of the patient showed poor control of blood sugar level while the patient underwent insulin treatment.
The patient was successfully shifted from insulin therapy to sulfonylurea; this shift happened according to the following regimen: week 1: Glibenclamide, 0.05 mg/kg/day, divided into 2 doses (1 in the morning and the other in the evening). Week 2: increase in Glibenclamide to 0.2 mg/kg/day and decrease in insulin dose by 25%. Week 3: increase in Glibenclamide to 0.3 mg/kg/day and decrease in insulin dose by 50%. Week 4:
increase in Glibenclamide to 0.4 mg/kg/day and decrease in insulin dose by 75%. Week 5: complete weaning from insulin. Table 2 shows the distribution of R201H pathological variant among the study group. Four previously recognized benign variants, namely, E23K, I337V, L270V, and A190A, were detected ( Table 3) .
Discussion
A total of 1% to 5% of all cases of diabetes mellitus in young people are monogenic forms. Despite this rare incidence, identifying certain pathological variant has been documented to be crucial because it could help the physician to modify the treatment regimen. 1 Accordingly, the aim of our study was to detect 1 of the most established pathological variant in PNDM, namely, Flanagan et al 16 defined the age of patients at the appearance of symptoms, in their study of KCNJ11 pathological variant. KCNJ11 had been sequenced in 239 nonconsanguineous patients recruited from 21 countries who had been diagnosed with diabetes mellitus before age 2 years. A total of 31 of the 120 patients (26%) diagnosed in the first 6 months of life harbored KCNJ11 pathological variant.
No pathological variant were detected in the 119 case individuals diagnosed after age 2 years. An exception to that finding was presented in a case reported by Mohamadi et al. 17 The patient was discovered to have DM at age 11.5 months, and a KCNJ11 pathological variant was identified, making this the oldest age at diagnosis of a KCNJ11 pathological variant-related case of ND. This case report supported the suggestion of increasing the age of genetic testing for monogenic causes of diabetes to younger than 12 months (rather than 6 months) at diagnosis. However, Wambach et al 18 reported that the youngest patient with familial PND developed the disorder as a result of heterozygous KCNJ11 pathological variant (R201H). This patient was successfully treated with oral sulfonylurea at day of life (DOL) 5, below the reported therapeutic range, without ever receiving insulin.
In the present study, 4 previously recognized benign variants were identified, namely, E23K, I337V, L270V, and A190A (1/17 [6.0%] was homozygous). The E23K and the I337V benign variants were completely linked, whereas only 1 patient had I337V without E23EK benign variant. These results agree with those of Gloyn et al 19 and Edghill et al, 20 who identified several previously identified benign variants, namely, E23K, A190A, L267L, L270V, I337V, K381K, and S385C. Sakura et al 21 were the first to identify 1 silent benign variant (A190A) and 4 missense benign variants (E23K, L270V, I337V, and S385C) in healthy individuals and individuals with type 2 diabetes mellitus. The E23K and I337V benign variants were completely linked. The common variants (E23K, 1337V, and L270V) were found with similar frequency in healthy subjects and those with diabetes mellitus. Individuals with diabetes mellitus who harbored these variants responded normally to sulfonylurea therapy. 
Conclusions and Recommendations
Identifying the heterozygous activating KCNJ11 pathological variant (p.R201H) in the Egyptian boy, who was clinically misdiagnosed as having type 1 diabetes mellitus at age 1.5 months, had led to a successful shift in his treatment regimen from insulin to sulfonylurea. This treatment shift resulted in stronger glycemic control and improvement of some complications (polyuria and repeated infections) for the patient.
These preliminary results suggest the importance of implementing this genetic diagnosis in all our patients who develop diabetes in the first 6 months of life. We also propose expanding the study to include investigating other gene pathological variant (eg, ABCC8 gene), especially in those patients aged 6 months or younger who test negative for KCNJ11 gene pathological variant. A prolonged follow-up period should be valuable to evaluate the long-term efficacy and adverse effects of sulfonylurea therapy. This molecular testing is particularly crucial in Egypt and other developing countries, not only due to the inconvenience of lifelong insulin therapy but also for financial and economic reasons.
In addition, in most forms of monogenic diabetes mellitus, the gene pathological variant is inherited and dominant. 1 Accordingly, we recommend screening parents and other family members for the pathological variant. This practice can help in modifying treatment for misdiagnosed patients. Also, it can aid in predicting whether someone is likely to develop a monogenic form of diabetes mellitus in the future, thus helping the treating physician to select the most appropriate treatment. LM
